Table 1 Baseline characteristics of patients initiated on insulin detemir or insulin glargine: SOLVE™ Turkish cohort

N

2395

491

Percentage completing the 24-week study (%)

76.2%

68.4%

Age (years)

56.8 ± 10.2

56.6 ± 10.3

0.7979

Female (%)

57.2%

59.5%

0.3468

Duration of Diabetes (years)

8.1 ± 5.6

8.6 ± 5.4

0.0279

Weight (kg)

79.8 ± 13.9

78.5 ± 13.0

0.0606

BMI (kg/m²)

29.6 ± 4.8

29.6 ± 4.8

0.9541

Previous medical history (%)

Microvascular disease

30.0%

31.6%

0.4663

Macrovascular disease

21.3%

19.8%

0.4347

Hypoglycaemia

3.8%

3.9%

0.8940

HbA_1c (%)

9.72 ± 1.74

9.24 ± 1.71

0.0033

HbA_1c (mmol/mol)

83 ± 19

77 ± 19

FBG (mg/dl)

233 ± 75

221 ± 68

0.0989

FBG (mmol/l)

12.9 ± 4.2

12.3 ± 3.7

Rate of minor Hypoglycaemia (events ppy)

0.37

0.59

0.0554

OAD Treatment at time of Insulin Initiation (%)

Number of OADs

0.0214

1 OAD

29.6%

26.3%

2 OADs

45.0%

51.8%

>2 OADs

25.4%

21.8%

Class of OAD

Metformin

81.9%

86.7%

0.0100

Sulphonylureas

55.5%

52.0%

0.1611

Glinides

21.6%

26.1%

0.0279

Thiazolidinediones

20.2%

18.8%

0.4745

α-glucosidase inhibitors

18.0%

10.8%

0.0001

DPP-IV inhibitors

1.8%

2.7%

0.2441